公开(公告)号：EP3313378A1

公开(公告)日：2018-05-02

申请号：EP16738291.0

申请日：2016-06-24

申请人： AbbVie Inc.

发明人： SEVER, Nancy ,  WESTEDT, Ulrich ,  LANDER, Ute ,  SCHNEIDER, Katrin ,  STEITZ, Benedikt ,  MUELLER, Thomas ,  REUL, Regina ,  OBERMILLER, Constanze ,  JAYASANKAR, Adivaraha ,  SIMON, Michael ,  GAO, Yi ,  HACH, Harald ,  KYEREMATENG, Samuel ,  ASMUS, Katharina ,  TONG, Ping ,  ZHU, Donghua ,  NARIS, Marius ,  GARRETT, Colleen

IPC分类号： A61K9/14 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K31/498 ,  A61P31/14

CPC分类号： A61K38/06 ,  A61K9/146 ,  A61K9/1688 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K2300/00

摘要： The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：EP3324941A1

公开(公告)日：2018-05-30

申请号：EP16745584.9

申请日：2016-07-18

申请人： AbbVie Inc.

发明人： ASMUS, Katharin ,  GAO, Yi ,  GARRETT, Colleen ,  HACH, Harald ,  JAYASANKAR, Adivaraha ,  KYEREMATENG, Samuel ,  LANDER, Ute ,  MUELLER, Thomas ,  NARIS, Marius ,  OBERMILLER, Constanze ,  REUL, Regina ,  SCHNEIDER, Katrin ,  SEVER, Nancy ,  SIIMON, Michael ,  STEITZ, Benedikt ,  TONG, Ping ,  WESTEDT, Ulrich ,  ZHU, Donghua

IPC分类号： A61K9/14 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K31/498 ,  A61P31/14

CPC分类号： A61K9/146 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/209 ,  A61K31/454 ,  A61K31/498

摘要： The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.